Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

Revumenib met the CR/CRh primary end point of the phase 2 AUGMENT-101 trial in NPM1-mutated acute myeloid leukemia.

Vinayak Venkataraman, MD
Personalized Initiatives Empower Patients to Actively Participate in Cancer Research

November 11th 2024

DLL3-TOPAbody
Preclinical Activity Support DLL3-TOPAbody in DLL3-Expressing SCLC and Other Tumors

November 8th 2024

Lung Cancer - stock.adobe.com
FDA Approval Sought for Sunvozertinib in Pretreated EGFR Exon 20+ Advanced NSCLC

November 8th 2024

Brian A. Van Tine, MD, PhD, of Washington University in St Louis
MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors

November 7th 2024

<1
...
107108109110111